Tarsus Pharmaceuticals, Inc. - Common Stock (TARS)

Tarsus Pharmaceuticals (NASDAQ:TARS) said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company seeks to expand its presence in eye care and enter the retina market. On an investor call discussin

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research published a report Wednesday alleging the company's sole commercial product relies on an illegal Medicare copay scheme. Here's what you should know.

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.

Tarsus (TARS) Q1 2026 Earnings Transcript

This ophthalmic biotech reported a notable insider sale as it advances treatments for Demodex blepharitis and other eye diseases.

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.

Tarsus (TARS) Q4 2025 Earnings Call Transcript

Tarsus Pharmaceuticals (TARS) combines explosive revenue growth with a strong technical setup, presenting a potential breakout opportunity for momentum investors.

A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.

Discover TARSUS PHARMACEUTICALS (TARS), a top growth stock with a perfect 10/10 technical rating and explosive 182% revenue growth, signaling strong upside potential.

Discover Tarsus Pharmaceuticals (TARS), a high-growth stock with strong fundamentals and a bullish technical setup poised for a potential breakout.

Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase

Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.